Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1141-1150

  Aziz, Atiqullah ^a,b   Fritsche, Hans Martin ^a   Gakis, Georgios ^c   Kluth, Luis A ^b   al Sayed Hassan, Fahmy ^c   Engel, Oliver ^b   Dahlem, Roland ^b   Otto, Wolfgang ^a   Gierth, Michael ^a   Denzinger, Stefan ^a   Schwentner, Christian ^c   Stenzl, Arnulf ^c   Shariat, Shahrokh F ^d   Fisch, Margit ^b   Burger, Maximilian ^a   Rink, Michael ^d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Comorbidity; Survival; Upper urinary tract; Urothelial carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COMORBIDITY; FEMALE; FOLLOW UP; HUMAN; HYDRONEPHROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MORTALITY; NEPHROURETERECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; NEPHRECTOMY; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL; TREATMENT OUTCOME; URETERAL NEOPLASMS; UROLOGIC NEOPLASMS;

AGED; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHRECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URETERAL NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84909626985     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.04.008     Document Type: Article

References (30)

1. Margulis V., Shariat S.F., Matin S.F., et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009, 115:1224-1233.
2. Rink M., Sjoberg D., Comploj E., et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 2012, 19:4337-4344.
3. Xylinas E., Kluth L.A., Crivelli J.J., et al. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Eur Urol 2013, 63:1134-1135.
4. Rieken M., Xylinas E., Kluth L., et al. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur J Surg Oncol 2013, 40:113-120.
5. Ehdaie B., Chromecki T.F., Lee R.K., et al. Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. J Urol 2011, 186:66-72.
6. Rink M., Xylinas E., Margulis V., et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013, 63:1082-1090.
7. Lughezzani G., Burger M., Margulis V., et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012, 62:100-114.
8. Saklad M. Grading of patients for surgical procedures. Anesthesiology 1941, 2:281-284.
9. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
10. Koppie T.M., Serio A.M., Vickers A.J., et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008, 112:2384-2392.
11. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
12. Berod A.A., Colin P., Yates D.R., et al. The role of American Society of Anesthesiologists scores in predicting urothelial carcinoma of the upper urinary tract outcome after radical nephroureterectomy: results from a national multi-institutional collaborative study. BJU Int 2012, 110:1035-1040.
13. Martinez-Salamanca J.I., Shariat S.F., Rodriguez J.C., et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2012, 109:1155-1161.
14. Morizane S., Iwamoto H., Masago T., et al. Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 2013, 45:99-106.
15. Rink M., Sharifi N., Fritsche H.M., et al. Impact of preoperative anemia on oncological outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 2013, 191:316-322.
16. Burger M., Shariat S.F., Fritsche H.M., et al. No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. World J Urol 2011, 29:465-472.
17. Rink M., Ehdaie B., Cha E.K., et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 2012, 62:677-684.
18. Mayr R., May M., Martini T., et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol 2012, 62:662-670.
19. Edge S.B., Byrd D.R., Compton C.C., et al. American Joint Committee on Cancer (AJCC) Staging Manual 2010, Springer, New York. 7th ed.
20. Epstein J.I., Amin M.B., Reuter V.R., et al. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998, 22:1435-1448.
21. Fritsche H.M., Novara G., Burger M., et al. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. Urol Oncol 2012, 30:666-672.
22. Zigeuner R., Shariat S.F., Margulis V., et al. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 2010, 57:575-581.
23. Hurel S., Rouprêt M., Ouzzane A., et al. Impact of lymphovascular invasion on oncological outcomes in patients with upper tract urothelial carcinoma after radical nephroureterectomy. BJU Int 2013, 111:1199-1207.
24. Harrell F.E., Lee K.L., Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387.
25. Froehner M., Koch R., Litz R.J., et al. Comorbidity is poor predictor of survival in patients undergoing radical prostatectomy after 70 years of age. Urology 2006, 68:583-586.
26. Kutikov A., Egleston B.L., Canter D., et al. Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. J Urol 2012, 188:2077-2083.
27. Ecke T.H., Gerullis H., Bartel P., et al. Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. Minerva Urol Nefrol 2009, 61:249-256.
28. Kawashima A., Nakai Y., Nakayama M., et al. The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multiinstitutional study. World J Urol 2012, 30:701-706.
29. Kluth L.A., Xylinas E., Kent M., et al. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. BJU Int 2013, [Epub ahead of print], doi: 10.1111/bju.12369.
30. Miller D.C., Taub D.A., Dunn R.L., et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J Urol 2003, 169:105-109.